AI assistant
Evotec SE — Regulatory Filings 2012
Nov 15, 2012
151_rns_2012-11-15_bdc2cd9c-c534-473f-ba9f-4a76c320dd2e.html
Regulatory Filings
Open in viewerOpens in your device viewer
News Details
Corporate | 15 November 2012 07:29
Evotec partners with Haplogen to develop drugs for infectious diseases
Evotec AG / Key word(s): Alliance
15.11.2012 / 07:29
Hamburg, Germany, Vienna, Austria - 15 November 2012: Evotec AG (Frankfurt
Stock Exchange: EVT, TecDAX) and Haplogen GmbH have signed a collaboration
agreement to discover and develop small molecules against viral infectious
diseases.
Under the agreement, Haplogen and Evotec will co-develop drugs against a
human protein that is essential for pathogenic viruses to infect their host
cell. This protein was discovered by Haplogen's powerful proprietary
technology to identify host factors for infectious human pathogens. Evotec
will further develop Haplogen's lead compounds and apply its drug discovery
platform to find additional small molecule inhibitors.
'This partnership will ensure that our therapeutic program advances with
increasing pace to discover molecules for clinical testing in those
patients that are at high risk of virus infections', says Georg Casari, CEO
of Haplogen. 'We are excited that Evotec shares our vision and has joined
forces on this first-in-class drug target.'
Mario Polywka, Chief Operating Officer of Evotec, explains: 'Part of
Evotec's strategy is to pursue innovative, early stage projects and develop
them to a partnering position before the clinic. We are delighted to
partner with Haplogen to optimize their protein inhibitors. Haplogen's
powerful target discovery technology is an excellent complement to Evotec's
small molecule discovery and development capabilities. We hope that this is
the start of a long-term relationship.'
Terms of the partnership were not disclosed.
ABOUT HAPLOGEN GMBH
Haplogen GmbH is a privately held biotechnology company with an entirely
novel target identification technology based on human haploid genetics and
a drug discovery pipeline in infectious diseases. Haplogen's mission is to
exploit human haploid genetics to improve human health.
FORWARD LOOKING STATEMENTS - Information set forth in this press release
contains forward-looking statements, which involve a number of risks and
uncertainties. The forward-looking statements contained herein represent
the judgement of Evotec as of the date of this report. Such forward-looking
statements are neither promises nor guarantees, but are subject to a
variety of
risks and uncertainties, many of which are beyond our control, and which
could cause actual results to differ materially from those contemplated in
these forward-looking statements. We expressly disclaim any obligation or
undertaking to release publicly any updates or revisions to any such
statements to reflect any change in our expectations or any change in
events, conditions or circumstances on which any such statement is based.
Contact Evotec AG:
Dr Mario Polywka, Chief Operating Officer, Phone: +44.(0)1235.441676,
[email protected]
End of Corporate News
15.11.2012 Dissemination of a Corporate News, transmitted by DGAP - a
company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
Language: English
Company: Evotec AG
Manfred Eigen Campus / Essener Bogen 7
22419 Hamburg
Germany
Phone: +49 (0)40 560 81-0
Fax: +49 (0)40 560 81-222
E-mail: [email protected]
Internet: www.evotec.com
ISIN: DE0005664809
WKN: 566480
Indices: TecDAX
Listed: Regulierter Markt in Frankfurt (Prime Standard);
Freiverkehr in Berlin, Düsseldorf, Hamburg, Hannover,
München, Stuttgart
End of News DGAP News-Service
193316 15.11.2012